Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

6.6%

8 terminated/withdrawn out of 121 trials

Success Rate

90.2%

+3.7% vs industry average

Late-Stage Pipeline

5%

6 trials in Phase 3/4

Results Transparency

4%

3 of 74 completed trials have results

Key Signals

16 recruiting3 with results6 terminated

Enrollment Performance

Analytics

N/A
36(38.3%)
Phase 2
35(37.2%)
Phase 1
17(18.1%)
Phase 3
5(5.3%)
Phase 4
1(1.1%)
94Total
N/A(36)
Phase 2(35)
Phase 1(17)
Phase 3(5)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (121)

Showing 20 of 121 trials
NCT04670016Completed

HRQL and Symptom Assessment for Patients With DIPG or Recurrent and Re-irradiated Brain Tumours and Their Caregivers

Role: collaborator

NCT07524114Recruiting

Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)

Role: collaborator

NCT05784428Not ApplicableRecruiting

Single vs. Multiple Fraction Trial of Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastases/Progression

Role: collaborator

NCT00160979Phase 2Completed

Transrectal Tumour Oxygen - US Army

Role: collaborator

NCT01999062Not ApplicableCompleted

Automated Breast Radiation Therapy Using an MR-Guided Process

Role: collaborator

NCT00188539Phase 2Active Not Recruiting

Cervix: Hypoxia, Interstitial Fluid Pressure and GSH Levels

Role: collaborator

NCT01761929Phase 2Completed

5 Fraction Stereotactic Body Radiation Therapy for Oligometastases Regimen, for Extra-Cranial Oligometastases

Role: collaborator

NCT01803542Phase 2Recruiting

Stereotactic Radiotherapy (SBRT) of Lung Metastasis

Role: collaborator

NCT04075305Recruiting

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

Role: collaborator

NCT06241677Not ApplicableRecruiting

Intravenous Thrombolytic Therapy in Acute Ischemic Stroke Patients on DOAC

Role: collaborator

NCT01505400Active Not Recruiting

Integrated Molecular Profiling in Advanced Cancers Trial

Role: collaborator

NCT02724488Active Not Recruiting

Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic Therapies

Role: collaborator

NCT06247449Not ApplicableRecruiting

MRI Screening for Brain Metastases Among Patients With Triple Negative or HER2+ Stage II or III Breast Cancer

Role: collaborator

NCT06781762Recruiting

Short-term Impacts of Endocrine Therapy on Cardiovascular and Brain Health Outcomes in Breast Cancer

Role: collaborator

NCT00715611Phase 2Active Not Recruiting

Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma

Role: collaborator

NCT05565313Active Not Recruiting

Predicting Radiological Extranodal Extension in Oropharyngeal Carcinoma Patients Using AI

Role: collaborator

NCT05196087Recruiting

Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)

Role: collaborator

NCT04848909Not ApplicableActive Not Recruiting

Stereotactic Body Radiotherapy (SBRT) Post Prostatectomy

Role: collaborator

NCT03168815Not ApplicableActive Not Recruiting

Low-Flow vs. High-Flow Nasal Cannula for Hypoxemic Immunocompromised Patients During Diagnostic Bronchoscopy

Role: collaborator

NCT06363266Not ApplicableRecruiting

A SMART Design to Optimize the Delivery of TEMPO for Men With Prostate Cancer and Their Caregivers

Role: collaborator